Abstract
To evaluate efficacy and safety in patients with ocular hypertension or open angle glaucoma changed to latanoprost/timolol fixed combination (LTFC). A prospective, multicentre, historical control in which qualified patients had their previous therapy substituted by LTFC and were followed for at least 2 months. In 1676 patients LTFC was continued in 93% throughout the observation period. In all patients LTFC reduced the intraocular pressure (IOP) from 20.6 (SD 3.8) to 17.7 (3.0) mm Hg (p<0.001) compared to previous monotherapies including latanoprost, timolol, alpha agonists or carbonic anhydrase inhibitors (CAI). LTFC provided more efficacy after changing from adjunctive therapies including: a beta blocker added to either CAI, alpha agonist, or pilocarpine, or CAI added to an alpha agonist, or latanoprost added to either CAI, alpha agonist, or beta blocker (unfixed combination), and travoprost added to timolol (p<0.007). LTFC was as effective as latanoprost used with dorzolamide/timolol fixed combination (-0.9 mm Hg, p = 0.1792). The most common reason to discontinue therapy was lack of efficacy (n = 70, 4%) and adverse event (n = 17, 1%). In a clinical setting, patients who have their monotherapy or adjunctive therapy substitu...Continue Reading
References
Jan 1, 1996·Ophthalmology·P Watson, J Stjernschantz
Sep 1, 1996·Clinical Cardiology·W C Stewart, W P Castelli
Dec 1, 1995·Ophthalmology·A Alm, J Stjernschantz
Jul 6, 2002·Archives of Ophthalmology·Eve J HigginbothamUNKNOWN Fixed Combination Investigative Group
Jun 5, 2003·Acta Ophthalmologica Scandinavica·William C StewartElizabeth D Sharpe
Jan 23, 2004·The British Journal of Ophthalmology·M DiestelhorstUNKNOWN European Latanoprost Fixed Combination Study Group
Mar 17, 2004·Ophthalmology·Dong H ShinUNKNOWN Fixed Combination Latanoprost/Timolol Study Group
Mar 24, 2004·Eye·W C StewartJ N Jenkins
Citations
Jun 15, 2007·Advances in Therapy·Stephan DunkerUNKNOWN Latanoprost/Timolol Fixed Combination Study Group
Oct 21, 2011·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Kenji InoueGoji Tomita
Mar 30, 2010·BMC Ophthalmology·Eric SellemJean Paul Renard
Sep 10, 2010·BMC Ophthalmology·Oliver SchwennPaul J Miller
May 28, 2010·Clinical Ophthalmology·Norbert PfeifferWilliam C Stewart
May 4, 2012·Clinical Ophthalmology·Kenji InoueGoji Tomita
Jun 14, 2012·Clinical Ophthalmology·Kenji InoueGoji Tomita
Sep 15, 2009·Clinical Ophthalmology·Makoto Ishikawa, Takeshi Yoshitomi
Jun 29, 2013·Expert Opinion on Pharmacotherapy·Anastasios Gp KonstasMurat Irkec
Dec 22, 2006·Expert Opinion on Drug Safety·Gábor Holló
Jul 16, 2009·Expert Opinion on Pharmacotherapy·Gemma Cm RossiCarmine Tinelli
Aug 21, 2008·Current Medical Research and Opinion·Marie-Noëlle LazaridouDavid Jaberoo
Apr 16, 2014·Journal of Ophthalmology·Kenji InoueGoji Tomita
Mar 22, 2013·Medical Decision Making : an International Journal of the Society for Medical Decision Making·Glenis J CraneJonathan D Karnon
Sep 21, 2018·Journal of Glaucoma·Kenji InoueGoji Tomita
Nov 28, 2007·Acta Ophthalmologica·Sriram SontyWilliam C Stewart
Aug 2, 2017·The Open Ophthalmology Journal·Kenji InoueGoji Tomita
Mar 29, 2019·Journal of Glaucoma·Florent AptelUNKNOWN and the T2347 Study Group
May 26, 2018·Japanese Journal of Ophthalmology·Kenji InoueGoji Tomita
Jun 6, 2019·Journal of Glaucoma·Florent AptelUNKNOWN T2347 Study Group
Sep 30, 2009·European Journal of Ophthalmology·William C StewartHeather M Mathis
Apr 7, 2007·European Journal of Ophthalmology·F TopouzisD Wells
Sep 30, 2014·Journal of Glaucoma·Erhan Ozyol, Pelin Ozyol